Neuropeptide Y Y1 receptors in vascular pharmacology

European Journal of Pharmacology

Volumn 349, Issue 1, 1998, Pages 1-14

  Franco Cereceda, Anders ^a   Liska, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Co transmission; Neuropeptide Y; Neuropeptide Y Y1 receptor; Pancreatic polypeptide; Peptide YY; Vascular tone

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; RECEPTOR SUBTYPE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y Y1 RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR; NORADRENALIN;

BLOOD VESSEL TONE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPATHETIC NERVE; VASCULAR DISEASE; ADRENERGIC SYSTEM; ANIMAL; BLOOD VESSEL; DRUG ANTAGONISM; HOMEOSTASIS; METABOLISM; MUSCLE TONE; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; BLOOD VESSELS; HOMEOSTASIS; HUMANS; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; NEUROPEPTIDE Y; NOREPINEPHRINE; RECEPTORS, NEUROPEPTIDE Y; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION;

EID: 0032523219     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00242-8     Document Type: Article

References (168)

1. Abel P.W., Han C., Noe B.D., McDonald J.K. Neuropeptide Y: vasoconstrictor effects and possible role in cerebral vasospasm after experimental subarachnoid haemorrhage. Brain Res. 463:1988;250-258.
2. 1 antagonist BIBP 3226. Br. J. Pharmacol. 116:1995;2245-2250.
3. Adrian T.E., Terenghi G., Brown M.J., Allen J.M., Bacarese-Hamilton A.J., Polak J.M., Bloom S.R. Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet. ii:1983;540-542.
4. 2 receptor binding in the nucleus tractus solitarius. Brain Res. 684:1995;159-164.
5. Ahlborg G., Lundberg J.M., Sollevi A. Vasoconstriction and metabolic effects of neuropeptide Y in man with special reference to splanchnic and renal clearance at rest and during exercise. Acta Physiol. Scand. 145:1991;139-149.
6. Aizawa Y., Murata M., Hayashi M., Funazaki T., Ito S., Shibata A. Vasoconstrictor effects of neuropeptide Y (NPY) on canine coronary circulation. Jpn. Circ. J. 49:1985;584-588.
7. Allen J.M., Bircham P.M.M., Edwards A.V., Tatemoto K., Bloom S.R. Neuropeptide Y (NPY) reduces myocardial perfusion and inhibits the force of contraction of the isolated rabbit heart. Regul. Pept. 6:1983;247-252.
8. Andriantsitohaina R., Stoclet J.C. Potentiation by neuropeptide Y of vasoconstriction in rat resistance arteries. Br. J. Pharmacol. 95:1988;419-428.
9. Balasubramaniam A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides. 18:1996;445-457.
10. Balasubramaniam A., Sheriff S. Neuropeptide Y (18-36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes. J. Biol. Chem. 265:1990;14724-14727.
11. Bard J.A., Walker M.W., Branchek T.A., Weinshank R.L. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide YY. J. Biol. Chem. 270:1995;26762-26765.
12. Benarroch E.E., Schmelzer J.D., Ward K.K., Nelson D.K., Low P.A. Noradrenergic and neuropeptide Y mechanisms in guanethidine-sympathectomized rats. Am. J. Physiol. 205:1990;R371-R375.
13. 1 receptor. Eur. J. Pharmacol. 316:1996;59-64.
14. 5 are involved in the renal effects of neuropeptide Y. Br. J. Pharmacol. 120:1997;1335-1343.
15. Blomquist A., Herzog H. Y receptor subtypes - how many more? Trends Neurosci. 20:1997;294-298.
16. Budai D., Vu H.Q., Duckles S.P. Endothelium removal does not affect potentiation by neuropeptide Y in rabbit ear artery. Eur. J. Pharmacol. 168:1989;97-100.
17. Burnstock G. Do some nerve cells release more than one transmitter? Neuroscience. 1:1976;239-248.
18. Burnstock, G., 1988. Some historical perspectives and future directions. In: Burnstock, G., Griffith, S.G. (Eds.), Nonadrenergic Innervation of Blood Vessels. CRC Press, Boca Raton, FL, pp. 1-14.
19. 1 receptor subtype. Regul. Pept. 46:1993;557-564.
20. Carlsson, A., 1965. Drugs which block the storage of 5-hydroxy-tryptamine and related amines. In: Erspamer, V.R. (Ed.), Handbook of Experimental Pharmacology. Springer, Berlin, pp. 529-592.
21. 2 agonist PYY (13-36) inhibit neurons of the dorsal motor nucleus of the vagus. Am. J. Physiol. 273:1997;R213-R218.
22. Clarke J.G., Davies G.J., Kerwin R., Hackett D., Larkin S., Dawbarn D. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. i:1987;1057-1059.
23. 2 receptor. Br. J. Pharmacol. 102:1991;359-364.
24. Corr L.A., Aberdeen J.A., Milner P., Lincoln J., Burnstock G. Sympathetic and non-sympathetic neuropeptide Y-containing nerves in the rat myocardium and coronary arteries. Circ. Res. 66:1990;1602-1609.
25. Corr L., Burnstock G., Poole-Wilson P. Effects of age and hyperlipidaemia on rabbit coronary responses to neuropeptide Y and the interaction with norepinephrine. Peptides. 14:1993;359-364.
26. Dahlöf C., Dahlöf P., Lundberg J.M. Neuropeptide Y (NPY): enhancement of blood pressure increase upon α-adrenoceptor activation and direct pressor effects in pithed rats. Eur. J. Pharmacol. 109:1985;289-292.
27. Dahlöf C., Dahlöf P., Tatemoto K., Lundberg J.M. Neuropeptide Y (NPY) reduces field stimulation-evoked release of noradrenaline and enhances the force of contraction in the rat portal vein. Naunyn-Schmiedeberg's Arch. Pharmacol. 328:1985;327-330.
28. Daly R.N., Hieble J.P. Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. Eur. J. Pharmacol. 138:1987;445-446.
29. Daniels A.J., Matthews J.E., Slepetis R.J., Jansen M., Viveros O.H., Tadepalli A., Harrington W., Heyer D., Landavozo A., Leban J.J., Spaltenstein A. High affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 92:1995;9067-9071.
30. 1 receptors. J. Neurochem. 69:1997;1048-1059.
31. Doods H.N., Krause J. Different neuropeptide Y receptor subtypes in rat and rabbit vas deferens. Eur. J. Pharmacol. 204:1991;101-103.
32. 1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther. 275:1995;136-142.
33. 1 receptor antagonist: a review of its pharmacological properties. Regul. Pept. 65:1996;71-77.
34. 1 receptor function in SK-N-MC cells by nitric oxide. Am. J. Physiol. 273:1997;C618-C621.
35. 3 receptor subtype. Mol. Brain Res. 26:1994;234-320.
36. Edvinsson L. Characterization of the cotractile effect of neuropeptide Y in feline cerebral arteries. Acta Physiol. Scand. 125:1985;33-41.
37. Edvinsson L., Emson P., McCulloch J., Tatemoto K., Uddman R. Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. Neurosci. Lett. 43:1983;79-84.
38. Edvinsson L., Ekblad R., Håkanson R., Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br. J. Pharmacol. 83:1984;519-525.
39. Edvinsson L., Ekman R., Thulin T. Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regul. Pept. 32:1991;287-297.
40. Edwall B., Gazelius B., Fazekas A., Theodorsson-Norheim E., Lundberg J.M. Neuropeptide Y (NPY) and sympathetic control of blood flow in oral mucosa and dental pulp in the cat. Acta Physiol. Scand. 25:1987;253-264.
41. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 8:1984;225-235.
42. Ekelund U., Erlinge D. In vivo receptor characterization of neuropeptide Y-induced effects in consecutive vascular sections of cat skeletal muscle. Br. J. Pharmacol. 120:1997;387-392.
43. 3H]BIBP 3226 Eur. J. Pharmacol. 278:1995;239-242.
44. Eva C., Keinänen K., Monyer H., Seeburg P., Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett. 271:1990;81-84.
45. Evéquoz D., Waeber B., Aubert J.-F., Flückiger J.P., Nussberger J., Brunner H.R. Neuropeptide Y prevents the blood pressure fall induced by endotoxin in conscious rats with adrenal medullectomy. Circ. Res. 62:1988;25-30.
46. Fallgren B., Arlock P., Jansen I., Edvinsson L. Neuropeptide Y in cerebrovascular function: comparison of membrane potential changes and vasomotor responses evoked by NPY and other vasoconstrictors in the guinea pig basilar artery. Neurosci. Lett. 114:1990;117-122.
47. Folkow B., Uvnäs B. The chemical transmission of vasoconstrictor impulses to the hindlimbs and the splanchnic region of the cat. Acta Physiol. Scand. 15:1948;365-388.
48. Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br. J. Pharmacol. 97:1989;968-972.
49. Franco-Cereceda A., Lundberg J.M. Potent effects of neuropeptide Y and calcitonin gene-related peptide on human coronary vascular tone in vitro. Acta Physiol. Scand. 131:1987;159-160.
50. Franco-Cereceda A., Lundberg J.M., Dahlöf C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol. Scand. 124:1985;361-369.
51. Franco-Cereceda A., Saria A., Lundberg J.M. Differential release of calcitonin gene-related peptide and neuropeptide Y from the isolated heart by capsaicin, ischaemia, nicotine, bradykinin and ouabain. Acta Physiol. Scand. 135:1989;173-187.
52. Franco-Cereceda A., Öwall A., Settergren G., Sollevi A., Lundberg J.M. Release of neuropeptide Y and noradrenaline from the human heart by aortic occlusion during coronary artery surgery. Cardiovasc. Res. 24:1990;242-246.
53. Franco-Cereceda A., Matran R., Alving K., Lundberg J.M. Sympathetic vascular control of the laryngeo-tracheal, bronchial and pulmonary circulation in the pig: evidence for non-adrenergic mechanisms involving neuropeptide Y. Acta Physiol. Scand. 155:1995;193-204.
54. Fredholm B.B., Jansen I., Edvinsson L. Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Acta Physiol. Scand. 124:1985;467-469.
55. Fried G., Lundberg J.M., Theodorsson-Norheim E. Subcellular storage and axonal transport of neuropeptide Y (NPY) in relation to catecholamines in the cat. Acta Physiol. Scand. 125:1985;145-154.
56. 1 receptor antagonist. Proc. Natl. Acad. Sci. USA. 87:1990;182-186.
57. Gardiner S.M., Bennett T., Compton A.M. Regional haemodynamic effects of neuropeptide Y, vasopressin and angiotensin II in conscious, unrestrained, Long-Evans and Brattleboro rats. J. Auton. Nerv. Syst. 24:1988;15-27.
58. 2) receptors and uses thereof. Int. Patent Application WO 95/21245.
59. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Withebread S., Hofbauer K.G., Taber R.I., Branchek T.A., Winshank R.L. A receptor subtype involved in neuropeptide Y-induced food intake. Nature. 382:1996;168-171.
60. 1-selective antagonist, BIBP 3226. Br. J. Pharmacol. 119:1996;1313-1318.
61. Glower W.E. Increased sensitivity of the rabbit ear artery to noradrenaline following perivascular nerve stimulation may be a response to neuropeptide Y released as co-transmitter. Clin. Exp. Pharmacol. Physiol. 12:1985;227-230.
62. Glower, W.E., 1986. Effect of neuropeptide Y (NPY) on calcium permeability in vascular smooth muscle. Proceedings of International Congress of Physiology Sciences, P318.06.
63. 2 receptors. Regul. Pept. 67:1996;33-37.
64. Gregor P., Feng Y., DeCarr L.B., Cornfield L.J., McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem. 271:1996;27776-27781.
65. Grundemar L., Wahlestedt C., Reis D.J. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J. Pharmacol. Exp. Ther. 258:1991;633-638.
66. Grundemar L., Jonas S.E., Mörner N., Högestätt E.D., Wahlestedt C., Håkanson R. Characterization of vascular neuropeptide Y receptors. Br. J. Pharmacol. 105:1992;45-50.
67. 2 receptors by substituted and truncated neuropeptide Y analogues: identification of signal epitopes. Eur. J. Pharmacol. 232:1993;271-278.
68. Haass M., Hock M., Richardt G., Schömig A. Neuropeptide Y differentiates between exocytotic and non-exocytotic noradrenaline release in guinea pig heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 340:1989;509-515.
69. Han S., Abel P.W. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J. Cardiovasc. Pharmacol. 9:1987;675-681.
70. Han C., Wang X., Fiscus R.R., Gu J., McDonald J.K. Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat. Neurosci. Lett. 104:1989;141-146.
71. Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., Selbie L.A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. U.S.A. 89:1992;5794-5798.
72. 2+ efflux from freshly isolated adult rat cardiomyocytes. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;456-762.
73. Hu Y., Bloomquist B.T., Cornfield L.J., DeCarr L.B., Flores-Riveros J.R., Friedman L., Jiang P., Lewis-Higgins L., Sadlowski Y., Schaefer J., Velazques N., McCaleb M.L. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behaviour. J. Biol. Chem. 42:1996;26315-26319.
74. Hughes A.D., Thom S.A.M., Martin G.N., Nielsen H., Hair W.M., Schachter M. Size and site-dependent heterogeneity of human vascular responses in vitro. J. Hypertens. 6:1988;S173-S175.
75. Hulting J., Sollevi A., Ullman B., Franco-Cereceda A., Lundberg J.M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc. Res. 24:1990;102-108.
76. Jackowski A., Crockard A., Burnstock G., Lincoln J. Alterations in serotonin and neuropeptide Y content of cerebrovascular sympathetic nerves following experimental subarachnoid haemorrhage. J. Cereb. Blood Flow Metab. 9:1989;271-279.
77. 3 receptors. Eur. J. Pharmacol. 278:1995;R3-R5.
78. Kaijser L., Pernow J., Berglund B., Grubbström J., Lundberg J.M. Neuropeptide Y release from human heart is enhanced during prolonged exercise in hypoxia. J. Appl. Physiol. 76:1994;1346-1349.
79. Kassis S., Olasmaa M., Terenius L., Fishman P.H. Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G protein. J. Biol. Chem. 262:1987;3429-3431.
80. Kim D., Durán W.T.R., Daniels A.J., Durán W.N. Novel neuropeptide Y receptor antagonists block vasoconstriction in the hamster cheek pouch microcirculation. Microvasc. Res. 53:1997;167-172.
81. Lacroix J.-S. Adrenergic and non-adrenergic mechanisms in sympathetic vascular control of the nasal mucosa. Acta Physiol. Scand. 136:1989;1-63. Suppl. 581.
82. Lacroix J.S., Stjärne P., Änggård A., Lundberg J.M. Sympathetic vascular control of the pig nasal mucosa: I. Increased resistance and capacitance vessel responses upon stimulation with irregular bursts compared to continuous impulses. Acta Physiol. Scand. 132:1988;83-90.
83. Lacroix J.S., Stjärne P., Änggård A., Lundberg J.M. Sympathetic vascular control of the pig nasal mucosa: II. Reserpine-resistant, non-adrenergic nervous responses in relation to neuropeptide Y and ATP. Acta Physiol. Scand. 133:1988;183-197.
84. 2 prejunctional receptor. Br. J. Pharmacol. 113:1994;479-484.
85. Laher I., Germann P., Bevan J.A. Neurogenically-evoked cerebral artery constriction is mediated by neuropeptide Y. Can. J. Physiol. Pharmacol. 72:1994;1086-1088.
86. Larhammar, D., 1997. Extraordinary structural diversity of NPY family receptors. In: Grundemar, L., Bloom, S.R. (Eds.), Neuropeptide Y and Drug Development. Academic Press, London, pp. 87-105.
87. 1 type. J. Biol. Chem. 267:1992;10935-10938.
88. Lee T.J.F., Su C., Bevan J.A. Neurogenic sympathetic vasoconstriction of the rabbit basilar artery. Circ. Res. 39:1976;120-126.
89. Lee T.F., Chiuch C.C., Adam T. Synaptic transmission of vasoconstrictor nerves in rabbit basilar artery. Eur. J. Pharmacol. 61:1980;55-70.
90. Levi G., Raiteri M. Carrier-mediated release of neurotransmitters. Trends Neurosci. 16:1993;415-419.
91. Linder L., Lautenschlager B.M., Haefeli W.E. Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo. Hypertension. 28:1996;483-487.
92. Linton-Dahlöf P. Modulatory interactions of neuropeptide Y (NPY) on sympathetic vascular tone. Acta Physiol. Scand. 137:1989;1-85. Suppl. 586.
93. 1 receptor antagonist BIBP 3226. Br. J. Pharmacol. 116:1995;2971-2982.
94. Lundberg J.M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to α-adrenoceptor blockade. Acta Physiol. Scand. 116:1982;393-402.
95. Lundberg J.M., Terenius L., Hökfelt T., Martling C.R., Tatemoto K., Mutt V. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic nerves and effects of NPY on sympathetic function. Acta Physiol. Scand. 116:1982;477-480.
96. Lundberg J.M., Änggård A., Theodorsson-Norheim E., Pernow J. Guanethidine-sensitive release of neuropeptide Y-like immunoreactivity in the cat spleen by sympathetic nerve stimulation. Neurosci. Lett. 52:1984;175-180.
97. Lundberg J.M., Pernow J., Tatemoto K., Dahlöf C. Pre- and postjunctional effects of NPY on sympathetic control of rat femoral artery. Acta Physiol. Scand. 123:1985;511-513.
98. Lundberg J.M., Saria A., Franco-Cereceda A., Hökfelt T., Terenius L., Goldstein M. Differential effects of reserpine and 6-hydroxydopamine on neuropeptide Y (NPY) and noradrenaline in peripheral neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 328:1985;331-340.
99. Lundberg J.M., Saria A., Franco-Cereceda A., Theodorsson-Norheim E. Mechanisms underlying changes in the contents of neuropeptide Y in cardiovascular nerves and adrenal gland induced by sympatholytic drugs. Acta Physiol. Scand. 124:1985;603-611.
100. Lundberg J.M., Rudehill A., Sollevi A., Hamberger B. Evidence for co-transmitter role of neuropeptide Y in the pig spleen. Br. J. Pharmacol. 96:1989;675-687.
101. Lundblad L., Änggård A., Saria A., Lundberg J.M. Neuropeptide Y and non-adrenergic sympathetic vascular control of the cat nasal mucosa. J. Auton. Nerv. Syst. 20:1987;189-197.
102. Lundell I., Blomqvist A.G., Berglund M.M., Schober D.A., Johnson D., Statnick M.A., Gadski R.A., Gehlert D.R., Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 270:1995;29123-29128.
103. Mabe Y., Pérez R., Tatemoto K., Huidobro-Toro J.P. Chemical sympathectomy reveals pre- and postsynaptic effects of neuropeptide Y (NPY) in the cardiovascular system. Experimentia. 43:1987;1018-1020.
104. MacLean M.R., Hiley C.R. Effect of neuropeptide Y on cardiac output, its distribution, regional blood flow and organ vascular resistances in the pithed rat. Br. J. Pharmacol. 99:1990;340-342.
105. Maisel A.S., Scott N.A., Motulsky H.J., Michel M.C., Boublik J.H., Rivier J.E., Ziegler M., Allen R.S., Brown M.R. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am. J. Med. 86:1989;43-48.
106. 1 receptor mechanisms in sympathetic vascular control. Acta Physiol. Scand. 160:1997;1-55. Suppl. 636.
107. McDonald J.K. NPY and related substances. Crit. Rev. Neurobiol. 4:1988;97-135.
108. Millar B.C., Schlüter K.-D., Zhou X.-J., McDermott B.J., Piper H.M. Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. Am. J. Physiol. 266:1994;C1271-C1277.
109. Minson R., McRitchie R., Chalmers J. Effects of neuropeptide Y on renal, mesenteric and hindlimb vascular beds of the conscious rabbit. J. Auton. Nerv. Syst. 27:1989;139-146.
110. Minth C., Bloom S., Polak J.M., Dixon J. Cloning, characterization and DNA sequence of a human cDNA encoding neuropeptide tyrosine. Proc. Natl. Acad. Sci. USA. 81:1984;4577-4581.
111. Modin A. Non-adrenergic, non-cholinergic vascular control with reference to neuropeptide Y, vasoactive intestinal polypeptide and nitric oxide. Acta Physiol. Scand. 151:1994;1-74. Suppl. 622.
112. Morris J.L. Roles of neuropeptide Y and noradrenaline in sympathetic neurotransmission to the thoracic vena cava and aorta of guinea pigs. Regul. Pept. 32:1991;297-310.
113. Morris J.L., Murphy R. Evidence that neuropeptide Y released from noradrenergic axons causes prolonged contraction of the guinea pig uterine artery. J. Auton. Nerv. Syst. 24:1988;241-249.
114. Morris J.L., Russel A.E., Kapoor V., Cain M.D., Elliot J.M. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J. Auton. Nerv. Syst. 17:1986;143-149.
115. Nagata M., Franco-Cereceda A., Saria A., Amann R., Lundberg J.M. Reserpine-induced depletion of neuropeptide Y in the guinea pig: tissue-specific effects and mechanisms of action. J. Auton. Nerv. Syst. 20:1987;257-263.
116. Nankova B., Kvetnansky R., Hiremagalur B., Sabban B., Rusnak M., Sabban E.L. Immobilization stress elevates gene expression for catecholamine biosynthetic enzymes and some neuropeptides in rat sympathetic ganglia-effects of adrenocorticotropin and glucocorticoids. Endocrinology. 137:1996;5597-5604.
117. 2 receptors in arterioles of the guinea pig small intestine. Br. J. Pharmacol. 115:1995;220-221.
118. Nield T.O. Actions of neuropeptide Y on innervated and denervated rat tail arteries. J. Physiol. 386:1987;19-30.
119. 1 receptors. J. Cardiovasc. Pharmacol. 28:1996;764-768.
120. Öhlén A., Persson M.G., Lindbom L., Gustafsson L.E., Hedqvist P. Nerve-induced non-adrenergic vasoconstriction and vasodilatation in skeletal muscle. Am. J. Physiol. 258:1990;H1334-H1338.
121. Pernow J. Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control. Acta Physiol. Scand. 133:1988;1-56. Suppl. 568.
122. Pernow J., Lundberg J.M. Neuropeptide Y induces potent contraction of arterial vascular smooth muscle via an endothelium-independent mechanism. Acta Physiol. Scand. 134:1988;157-158.
123. Pernow J., Lundberg J.M. Release and vasoconstrictor effects of neuropeptide Y in relation to non-adrenergic sympathetic control of renal blood flow in the pig. Acta Physiol. Scand. 136:1989;507-517.
124. Pernow J., Lundberg J.M., Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 40:1987;47-54.
125. Pernow J., Svenberg T., Lundberg J.M. Action of calcium antagonists in pre- and postjunctional effects of neuropeptide Y on human peripheral blood vessels in vitro. Eur. J. Pharmacol. 136:1987;207-218.
126. 2 receptor of neuropeptide Y. Eur. J. Pharmacol. 327:1997;163-167.
127. 2 neuropeptide Y receptors. Regul. Pept. 54:1994;489-493.
128. Potter E.K. Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y? Neurosci. Lett. 54:1985;117-121.
129. Prieto D., Hernández M., Rivera L., Gracía-Sacristán A., Simonsen U. Distribution and functional effects of neuropeptide Y on equine ureteral smooth muscle and resistance arteries. Regul. Pept. 69:1997;155-165.
130. 1 receptors are involved in the vasoconstriction caused by human sympathetic nerve stimulation. Eur. J. Pharmacol. 329:1996;79-83.
131. Revington M., McCloskey D.I. Neuropeptide Y and control of vascular resistance in skeletal muscle. Regul. Pept. 23:1988;331-342.
132. Richardt G., Haass M., Neeb S., Hock M., Lang R.E., Schömig A. Nicotine-induced release of noradrenaline and neuropeptide Y in guinea pig heart. Klin. Wochenschr. 66:1988;21-27. Suppl. XI.
133. Rioux F., Bachelard H., Martel J.C., St-Pierre S. The vasoconstrictor effect of neuropeptide Y and related peptides in the guinea pig isolated heart. Peptides. 7:1986;27-31.
134. Rose P.M., Fernandes P., Lynch J.S., Frazier S.T., Fisher S.M., Kodukula K., Kienzle B., Seethala R. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J. Biol. Chem. 270:1995;22661-22664.
135. Rosell S., Sedvall G. The rate of disappearance of vasoconstrictor responses to sympathetic chain stimulation after reserpine treatment. Acta Physiol. Scand. 56:1962;306-314.
136. Rudehill A., Sollevi A., Franco-Cereceda A., Lundberg J.M. Neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects. Peptides. 7:1986;821-826.
137. Rudehill A., Olcén M., Sollevi A., Hamberger B., Lundberg J.M. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor effects in the pig. Acta Physiol. Scand. 131:1987;517-523.
138. 1 receptor antagonist: BIBP 3226. Eur. J. Pharmacol. 271:1994;R11-R13.
139. 1 receptor binding site. In: Grundemar, L., Bloom, S.R. (Eds.), Neuropeptide Y and Drug Development. Academic Press, London, pp. 175-190.
140. Rump L.C., Riess M., Schwertfeger E., Michel M.C., Bohmann C., Schollmeyer P. Prejunctional neuropeptide Y receptors in human kidney and atrium. J. Cardiovasc. Pharmacol. 29:1997;656-661.
141. Saville V.L., Maynard K.I., Burnstock G. Neuropeptide Y potentiates purinergic as well as adrenergic responses of the rabbit ear artery. Eur. J. Pharmacol. 176:1990;117-125.
142. Schalling M., Franco-Cereceda A., Hökfelt T., Persson H., Lundberg J.M. Increased neuropeptide Y messenger RNA and peptide content in sympathetic ganglia after reserpine pretreatment. Eur. J. Pharmacol. 156:1988;419-420.
143. Schömig A., Dart A.M., Dietz R., Mayer E., Kübler W. Release of endogenous catecholamines in the ischaemic myocardium of the rat. Circ. Res. 55:1984;689-701.
144. Schömig A., Dart A.M., Dietz R., Kübler W., Mayer E. Paradoxical role of neuronal uptake for the locally mediated release of endogenous noradrenaline in the ischaemic myocardium. J. Cardiovasc. Pharmacol. 7:1985;S40-S44.
145. Shigeri Y., Fujimoto M. Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci. Lett. 149:1993;19-22.
146. 2+ concentration via phospholipase C-dependent pathway in porcine aortic smooth muscle cells. J. Biochem. 118:1995;515-520.
147. Sedvall G., Thorson J. Adrenergic transmission at vasoconstrictor nerve terminals partially depleted of noradrenaline. Acta Physiol. Scand. 64:1965;251-258.
148. 1 receptor antagonists. In: Grundemar, L., Bloom, S.R. (Eds.), Neuropeptide Y and Drug Development. Academic Press, London, pp. 157-174.
149. 1 receptors. Soc. Neurosci. Abstr. 20:1994;907.
150. 1 receptor antagonist. FEBS Lett. 362:1995;192-196.
151. Stofer W.D., Fatherazi S., Horn J.P. Neuropeptide Y mimics a non-adrenergic component of sympathetic vasoconstriction in the bullfrog. J. Auton. Nerv. Syst. 31:1990;141-152.
152. Taddei S., Salvetti A., Pedrinelli R. Persistence of sympathetic-mediated forearm vasoconstriction after α-blockade in hypertensive patients. Circulation. 80:1989;485-490.
153. Tadepalli A.S., Harrington W.W., Hashim M.A., Matthews J., Leban J.J., Spaltenstein A., Daniels A.J. Haemodynamic characterization of a novel neuropeptide Y receptor antagonist. J. Cardiovasc. Pharmacol. 27:1996;712-718.
154. Tanaka E., Mori H., Chujo M., Yamakawa A., Mohammed M.U., Shinozaki Y., Tobita K., Sekka T., Ito K., Nakazawa H. Coronary vasoconstrictive effects of neuropeptide Y and their modulation by the ATP-sensitive potassium channel in anesthetized dogs. J. Am. Coll. Cardiol. 29:1997;1380-1389.
155. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 296:1982;659-660.
156. Thureson-Klein, Å., Klein, R.L., Duncan, R.W., Kong, J.Y., 1987. Large noradrenergic vesicles may continue to function in neuropeptide release in reserpinized pigs. In: Nobin, A., Owman, C., Arneklo-Nobin, B. (Eds.), Neuronal Messengers in Vascular Function. Elsevier, Amsterdam, pp. 399-406.
157. Ullman B., Franco-Cereceda A., Hulting J., Lundberg J.M., Sollevi A. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J. Int. Med. 228:1990;583-589.
158. Waeber B., Aubert J.-F., Corder R., Evéquoz D., Nussberger J., Gaillard R. Cardiovascular effects of neuropeptide Y. Am. J. Hypertens. 1:1988;193-199.
159. Wahlestedt C., Edvinsson L., Ekblad E., Håkansson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J. Pharmacol. Exp. Ther. 234:1985;735-741.
160. Wahlestedt C., Yanaihara N., Håkanson R. Evidence for different pre- and postjunctional receptors for neuropeptide Y and related peptides. Regul. Pept. 13:1986;307-318.
161. 2 receptors. In: Nobin, A., Owman, C., Arneklo-Nobin, B. (Eds.), Neuronal Messengers in Vascular Function. Elsevier, Amsterdam, pp. 231-242.
162. Wahlestedt C., Håkanson R., Vaz C.A., Zukowska-Grojec Z. Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am. J. Physiol. 258:1990;R736-R742.
163. Watson J.D., Sury M.R., Corder R., Carson R., Bouloux P.M., Lowry P.J. Plasma levels of neuropeptide Y are increased in human sepsis but are unchanged during canine endotoxin shock despite raised catecholamine concentrations. J. Endocrinol. 116:1988;421-426.
164. Westfall T.C., Martin J., Chen X., Ciarleglio A., Carpentier S., Henderson K. Cardiovascular effects and modulation of noradrenergic neurotransmission following central and peripheral administration of neuropeptide Y. Synapse. 2:1988;299-307.
165. 5-like receptors. Nature Med. 3:1997;761-764.
166. 2-adrenoceptors by neuropeptide Y receptor subtypes in the nucleus tractus solitarii. Eur. J. Pharmacol. 271:1994;201-212.
167. 1 receptor contribute to blood pressure control in the spontaneously hypertensive rat? J. Hypertens. 15:1997;19-27.
168. 1 receptors. Am. J. Physiol. 270:1996;H796-H800.